Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30470561 | 1.00 | NPC1 (0.39) | NPC1DGAT1MAPTATML3MBTL1 | |
| SCHEMBL29081529 | 0.86 | NPC1 (0.40) | NPC1DGAT1MAPTATML3MBTL1 | |
| SCHEMBL14800179 | 0.80 | NPC1 (0.42) | NPC1DGAT1MAPT | |
| SCHEMBL18810435 | 0.77 | DGAT1 (0.46) | NPC1DGAT1 | |
| SCHEMBL30552683 | 0.77 | DGAT1 (0.46) | NPC1DGAT1 | |
| SCHEMBL25374677 | 0.77 | DGAT1 (0.36) | NPC1DGAT1 | |
| SCHEMBL31609643 | 0.76 | NPC1 (0.37) | NPC1DGAT1MAPT | |
| SCHEMBL637196 | 0.75 | NPC1 (0.42) | NPC1DGAT1MAPTPOLB | |
| SCHEMBL1542329 | 0.75 | NPC1 (0.40) | NPC1DGAT1MAPTPOLB | |
| SCHEMBL29861932 | 0.75 | NPC1 (0.43) | NPC1DGAT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | NPC1 39/4885DGAT1 4031/4885MAPT 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.